Who Will Likely Benefit from the Stegmann Canal Expander®?
Most anyone who is a candidate for canaloplasty should also benefit from placement of the Stegmann Canal Expander®. At the time of this writing, however, only those outside of the USA can do so as the FDA has yet to approve this device.
Stegmann Canal Expander® – Summary
Canaloplasty already offers an impressive IOP lowering benefit with minimal risk to the patient with glaucoma. However, it is a technically challenging and time-consuming surgery to perform. The addition of the Stegmann Canal Expander® may provide even greater IOP lowering benefit. I am looking forward to future studies comparing canaloplasty with the Stegmann Canal Expander® to trabeculectomy. If, as I expect to be the case, there is no significant IOP lowering benefit with trabeculectomy but much greater risk with trabeculectomy, then it is my hope that more US-based surgeons will make the effort to learn this technique for the benefit of their patients.
- Grieshaber MC, Schoetzau A, Grieshaber HR, Stegmann R. Canaloplasty with Stegmann Canal Expander for primary open-angle glaucoma: two-year clinical results. Acta Ophthalmol. 2017 [published online prior to print].
- Lewis RA, von W, Tetz M, Koerber N,Kearney JR, Shingleton BJ & SamuelsonTW (2009): Canaloplasty: circumferential viscodilation and tensioning of Schlemm canal using a ﬂexible microcatheter for the treatment of open-angle glaucoma in adults: two-year interim clinical study results. JCataract Refract Surg 35: 814–824.
- Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment Outcomes in the Tube versus Trabeculectomy (TVT) Study After Five Years of Follow-up. Am J Ophthalmol 2012;153:789 – 803.
Sick of High IOPs? Tired of taking Drops?
In The Same Series:
- Canaloplasty with the Stegmann Canal Expander®
- How Well Does the Stegmann Canal Expander® Work?
- Risks of Canaloplasty with the Stegmann Canal Expander®
- Comparison to Canaloplasty without the Stegmann Canal Expander®
- Who Will Likely Benefit from the Stegmann Canal Expander®?
David Richardson, MD
Medical Director, San Marino Eye
David Richardson, M.D. is recognized as one of the top cataract and glaucoma surgeons in the US and is among an elite group of glaucoma surgeons in the country performing the highly specialized canaloplasty procedure. Morever, Dr. Richardson is one of only a few surgeons in the greater Los Angeles area that performs MicroPulse P3™ "Cyclophotocoagulation" (MP3) glaucoma laser surgery. Dr. Richardson graduated Magna Cum Laude from the University of Southern California and earned his Medical Degree from Harvard Medical School. He completed his ophthalmology residency at the LAC+USC Medical Center/ Doheny Eye Institute. Dr. Richardson is also an Ambassador of Glaucoma Research Foundation.